Proprietary Technology News Today

On May 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), sold 3,000 shares of the company.

Don't get too caught up in the AI hype. Learn how to separate the long-term winners from the temporary market darlings.

POMPANO BEACH, Fla., March 28, 2024--ONX Homes Launches X+ Construction Systems Factory in Pompano Beach, Florida, nation's most advanced homebuilding factory of climate resilient homes.

Miami, Florida and Toronto, Ontario--(Newsfile Corp. - March 13, 2024) - Sekur Private Data Ltd. (OTCQB: SWISF) (CSE: SKUR) (FSE: GDT0) ("Sekur" or the "Company"), a leading Swiss hosted secure and private communications platform, outlines solutions to protect enterprise and small to medium-sized business (SMB) owners from the growing menace of bad actor cyber threats. With statistics indicating the escalating costs of ransomware attacks on businesses, during the crucial US p...

Dissecting the Financials and Future Prospects of Fleetcor Technologies Inc (FLT)

Unveiling the Strengths and Challenges: A Deep Dive into Interactive Brokers Group Inc (IBKR) SWOT Analysis

WPP plc (NYSE:WPP) Q4 2023 Earnings Call Transcript February 22, 2024 WPP plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Mark Read: Thank you very much and welcome everybody to WPP’s Preliminary Results for 2023. I’m Mark Read. I’m joined […]

Fleet telematics provider Motive Technologies filed a lawsuit Thursday alleging Samsara Inc. copied and used its proprietary technology and patents. The post Motive countersues fleet tech rival Samsara over patent infringement appeared first on FreightWaves.

▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating CRISPR/Cas Technology BOSTON, Feb. 15, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that New Drug Part has secured a potent anti-cancer candidate, PHAGERIA®, with broad antimicrobial activity against ETBF (Enterotoxige...

Steven Cunningham, the Chief Financial Officer of Enova International Inc, executed a sale of 17,548 shares of the company on February 9, 2024, according to a recent SEC Filing.